Clinical Trials Logo

X-Linked Retinitis Pigmentosa clinical trials

View clinical trials related to X-Linked Retinitis Pigmentosa.

Filter by:

NCT ID: NCT04312672 Active, not recruiting - Clinical trials for X-Linked Retinitis Pigmentosa

Long-term Follow-up Gene Therapy Study for RPGR- XLRP

Start date: July 31, 2017
Phase:
Study type: Observational

This is a long-term follow-up study assessing safety of patients for up to 60 months following advanced therapy investigational medicinal product (ATIMP) AAV5-hRKp.RPGR vector in participants with XLRP caused by mutations in RPGR.

NCT ID: NCT03584165 Enrolling by invitation - Choroideremia Clinical Trials

Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa

SOLSTICE
Start date: June 4, 2018
Phase: Phase 3
Study type: Interventional

The objective of the study is to evaluate the long-term safety and efficacy of a sub-retinal injection of BIIB111 in participants with Choroideremia (CHM) who have been previously treated with BIIB111 and who have exited an antecedent study; these treated participants will be compared with untreated control participants who have exited the STAR (NCT03496012) study and BIIB112 in participants with X-linked retinitis pigmentosa (XLRP) who have been previously treated with BIIB112 and who have exited an antecedent study.

NCT ID: NCT03316560 Active, not recruiting - Clinical trials for X-Linked Retinitis Pigmentosa

Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations

HORIZON
Start date: April 16, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector (rAAV2tYF-GRK1-RPGR) in patients with X-linked retinitis pigmentosa caused by RPGR mutations.

NCT ID: NCT03314207 Completed - Clinical trials for X-Linked Retinitis Pigmentosa

Clinical Evaluation of Patients With X-linked Retinitis Pigmentosa (XLRP)

Start date: December 1, 2017
Phase:
Study type: Observational

The purpose of this study is to evaluate subjects with X-linked retinitis pigmentosa caused by RPGR-ORF15 mutations in a clinical setting to fully characterize their condition, measure testing variability, and estimate rates of progression of clinical parameters.

NCT ID: NCT03252847 Completed - Clinical trials for X-Linked Retinitis Pigmentosa

Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR)

Start date: July 14, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The Phase 1 part of the study is a dose escalation of subretinal administration of AAV2/5 vector to assess the safety of this vector in participants with XLRP caused by mutations in RPGR. The Phase 2 part of the study is a cohort expansion of subretinal administration of AAV2/5 vector to assess the safety and efficacy of this vector in participants with XLRP caused by mutations in RPGR.

NCT ID: NCT03116113 Completed - Clinical trials for X-Linked Retinitis Pigmentosa

A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112

XIRIUS
Start date: March 8, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of the study is to evaluate the safety, tolerability and efficacy of a single sub-retinal injection of BIIB112 in participants with X-linked retinitis pigmentosa (XLRP).